Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro Inc.

Division of GlaxoSmithKline PLC
www.tesarobio.com

Latest From Tesaro Inc.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

ImmunoOncology Japan

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Drug Review Drug Approval Standards

AZ's Lynparza Gets Prostate Cancer Priority Review

The race is firmly on to be the first PARP inhibitor approved for metastatic castration-resistant prostate cancer, with the FDA giving a speedy review to AstraZeneca and Merck & Co's Lynparza just days after granting the same to Clovis Oncology's Rubraca.

Drug Review Cancer

China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche

Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.

China Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Lonnie Moulder, CEO
    Timothy Pearson, EVP, CFO
    Mary Lynne Hedley, PhD, Pres. & COO
    Grant C Bogle, SVP, Chief Commercial Officer
    William Aitchison, PhD, SVP, Technical ops
    Allene Diaz, SVP, Global Commercial Development
    Joseph Farmer, SVP, General Counsel & Corp Secretary
    Martin Huber, MD, SVP, CMO
    Jennifer Jackson, PhD, SVP, Global RA and QA
    Orlando Oliveira, SVP, International
  • Contact Info
  • Tesaro Inc.
    Phone: (339) 970-0900
    1000 Winter St.
    Ste. 3300
    Waltham, MA 02451
    USA
UsernamePublicRestriction

Register